| 1A. Paolo Fundarò; | | | 1B. Mark Pruzanski, M.D.; | | | 1C. Srinivas Akkaraju, M.D., Ph.D.; | |
| 1D. Luca Benatti, Ph.D.; | | | 1E. Daniel Bradbury; | | | 1F. Keith Gottesdiener, M.D.; | |
| 1G. Nancy Miller-Rich; | | | 1H. Gino Santini; | | | 1I. Glenn Sblendorio; and | |
| 1J. Daniel Welch. | | | |
| | | Page | | |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
13 | | | |||||
| | | | 14 | |||
| | ||||||
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
27 | | | |||||
| | | Page | | |||
| | | | 28 | | | |
| | | | 30 | | | |
| | | | 33 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | |
Director | | Age | | Director Since | | | Age | | Director Since | | ||||||||||||||||
Paolo Fundarò(1) | | | | 45 | | | | | 2006 | | | | | | 46 | | | | | 2006 | | | ||||
Mark Pruzanski, M.D. | | | | 51 | | | | | 2002 | | | | | | 52 | | | | | 2002 | | | ||||
Srinivas Akkaraju, M.D., Ph.D.(2) | | | | 51 | | | | | 2012 | | | | | | 52 | | | | | 2012 | | | ||||
Luca Benatti, Ph.D.(2)(3) | | | | 58 | | | | | 2014 | | | | | | 59 | | | | | 2014 | | | ||||
Daniel Bradbury(3)(4) | | | | 58 | | | | | 2016 | | | | | | 59 | | | | | 2016 | | | ||||
Keith Gottesdiener, M.D.(2) | | | | 65 | | | | | 2016 | | | | | | 66 | | | | | 2016 | | | ||||
Nancy Miller-Rich(5) | | | | 60 | | | | | 2018 | | | | | | 61 | | | | | 2018 | | | ||||
Gino Santini(4)(5)(6) | | | | 62 | | | | | 2015 | | | |||||||||||||||
Gino Santini(4)(5)(6) | | | | 63 | | | | | 2015 | | ��� | |||||||||||||||
Glenn Sblendorio(4) | | | | 63 | | | | | 2014 | | | | | | 64 | | | | | 2014 | | | ||||
Daniel Welch(3)(5) | | | | 61 | | | | | 2015 | | | | | | 62 | | | | | 2015 | | |
Membership | | | Chairperson | | | Other Members | | ||||||
Board of Directors. | | | | $ | 80,000 | | | | | $ | 50,000 | | |
Audit Committee | | | | $ | 20,000 | | | | | $ | 10,000 | | |
Compensation Committee | | | | $ | 15,000 | | | | | $ | 7,500 | | |
Nominating and Governance Committee | | | | $ | 10,000 | | | | | $ | 5,000 | | |
Research and Development Committee | | | | $ | 10,000 | | | | | $ | 5,000 | | |
Name | | Fees Earned or Paid in Cash ($) | | Stock Awards ($)(10) | | Option Awards ($)(10) | | Total ($) | | | Fees Earned or Paid in Cash ($) | | Stock Awards ($)(10) | | Option Awards ($)(10) | | Total ($) | | ||||||||||||||||||||||||||||||||
Paolo Fundarò | | | | 80,000(1) | | | | | 152,109 | | | | | 132,261 | | | | | 364,370 | | | | | | 80,000(1) | | | | | 129,133 | | | | | 132,223 | | | | | 341,356 | | | ||||||||
Srinivas Akkaraju, M.D., Ph.D. | | | | 59,516(2) | | | | | 152,109 | | | | | 132,261 | | | | | 343,886 | | | | | | 55,000(2) | | | | | 129,133 | | | | | 132,223 | | | | | 316,356 | | | ||||||||
Luca Benatti, Ph.D. | | | | 65,000(3) | | | | | 152,109 | | | | | 132,261 | | | | | 349,370 | | | | | | 65,000(3) | | | | | 129,133 | | | | | 132,223 | | | | | 326,356 | | | ||||||||
Daniel Bradbury | | | | 65,000(4) | | | | | 152,109 | | | | | 132,261 | | | | | 349,370 | | | | | | 65,000(4) | | | | | 129,133 | | | | | 132,223 | | | | | 326,356 | | | ||||||||
Keith Gottesdiener, M.D. | | | | 55,000(5) | | | | | 152,109 | | | | | 132,261 | | | | | 339,370 | | | | | | 55,000(5) | | | | | 129,133 | | | | | 132,223 | | | | | 316,356 | | | ||||||||
Nancy Miller-Rich | | | | 37,325(6) | | | | | 372,230 | | | | | 369,831 | | | | | 779,386 | | | | | | 57,500(6) | | | | | 129,133 | | | | | 132,223 | | | | | 318,856 | | | ||||||||
Gino Santini | | | | 75,000(7) | | | | | 152,109 | | | | | 132,261 | | | | | 359,370 | | | | | | 75,000(7) | | | | | 129,133 | | | | | 132,223 | | | | | 336,356 | | | ||||||||
Glenn Sblendorio | | | | 70,000(8) | | | | | 152,109 | | | | | 132,261 | | | | | 354,370 | | | | | | 70,000(8) | | | | | 129,133 | | | | | 132,223 | | | | | 331,356 | | | ||||||||
Daniel Welch | | | | 67,500(9) | | | | | 152,109 | | | | | 132,261 | | | | | 351,870 | | | | | | 67,500(9) | | | | | 129,133 | | | | | 132,223 | | | | | 328,856 | | |
| | Shares Beneficially Owned(7) | | | Shares Beneficially Owned(9) | | ||||||||||||||||||||
Name and Address | | Number of Shares | | Percentage of Common Stock | | | Number of Shares | | Percentage of Common Stock | | ||||||||||||||||
5% Stockholders: | | | | | | | | | | | | | | | | | | | | | | | ||||
Genextra S.p.A.(1) | | | | 6,095,578 | | | | | 20.5% | | | | | | 6,095,578 | | | | | 18.5% | | | ||||
FMR LLC(2) | | | | 4,448,170 | | | | | 14.9% | | | | | | 4,919,116 | | | | | 14.9% | | | ||||
BlackRock, Inc.(3) | | | | 2,032,287 | | | | | 6.8% | | | | | | 2,314,468 | | | | | 7.0% | | | ||||
The Vanguard Group(4) | | | | 2,006,622 | | | | | 6.7% | | | | | | 2,296,438 | | | | | 7.0% | | | ||||
Directors and Executive Officers: | | | | | | | | | | | | | | | | | | | | | | | ||||
Paolo Fundarò | | | | 28,250 | | | | | * | | | | | | 6,129,142 | | | | | 18.6% | | | ||||
Mark Pruzanski, M.D. | | | | 822,998 | | | | | 2.7% | | | | | | 787,855 | | | | | 2.4% | | | ||||
Srinivas Akkaraju, M.D., Ph.D. | | | | 240,279 | | | | | * | | | | | | 438,344 | | | | | 1.3% | | | ||||
Luca Benatti, Ph.D. | | | | 15,039 | | | | | * | | | | | | 21,553 | | | | | * | | | ||||
Daniel Bradbury | | | | 20,344 | | | | | * | | | | | | 26,723 | | | | | * | | | ||||
Keith Gottesdiener, M.D. | | | | 13,703 | | | | | * | | | | | | 20,082 | | | | | * | | | ||||
Nancy Miller-Rich | | | | 4,020 | | | | | * | | | | | | 14,809 | | | | | * | | | ||||
Gino Santini | | | | 15,596 | | | | | * | | | | | | 20,910 | | | | | * | | | ||||
Glenn Sblendorio | | | | 14,199 | | | | | * | | | | | | 19,513 | | | | | * | | | ||||
Daniel Welch | | | | 14,777 | | | | | * | | | | | | 20,091 | | | | | * | | | ||||
Gail Cawkwell, M.D., Ph.D. | | | | 11,060 | | | | | * | | | |||||||||||||||
Jerome Durso | | | | 33,588 | | | | | * | | | |||||||||||||||
Jerome Durso. | | | | 50,857 | | | | | * | | | |||||||||||||||
Sandip Kapadia | | | | 41,914 | | | | | * | | | | | | 54,264 | | | | | * | | | ||||
Richard Kim | | | | 32,751 | | | | | * | | | |||||||||||||||
Ryan Sullivan | | | | 32,995 | | | | | * | | | | | | 30,456 | | | | | * | | | ||||
All directors and executive officers as group (19 persons) | | | | 1,516,043 | | | | | 5.0% | | | | | | 7,812,414 | | | | | 23.7% | | |
Name | | | Age | | | Position | |
Mark Pruzanski, M.D. | | | | | President and Chief Executive Officer | | |
Jerome Durso | | | | | Chief Operating Officer | | |
Lisa Bright | | | | | President, International | | |
Jason Campagna, M.D., Ph.D. | | | 50 | | | Chief Medical Officer | |
Gail Cawkwell, M.D., Ph.D. | | | | | SVP, Medical Affairs, Safety & Pharmacovigilance | | |
David Ford | | | | | Chief Human Resources Officer | | |
Sandip Kapadia | | | | | Chief Financial Officer and Treasurer | | |
Richard Kim | | | | | President, U.S. Commercial & Strategic Marketing | | |
Ryan Sullivan | | | | | General Counsel and Secretary | | |
Christian Weyer, M.D., M.A.S. | | | | | EVP, Research & Development | |
Name | | | Title | |
Mark Pruzanski, M.D. | | | President and Chief Executive Officer (“CEO”) | |
Sandip Kapadia | | | Chief Financial Officer and Treasurer | |
Jerome Durso | | | Chief Operating Officer | |
Ryan Sullivan | | | General Counsel and Secretary | |
| | |
| | | | |||||
| | | | | ✓ ✓ TSR-Based Performance Stock Unit Awards. In | | |
| | KEY BUSINESS ACHIEVEMENTS | | | ||||||||||||
| | ✓ | | | | Achieved Positive Topline Results in Pivotal Phase 3 REGENERATE trial. In February 2019, we announced positive topline results from the planned 18-month interim analysis of our pivotal Phase 3 clinical trial of obeticholic acid (“OCA”) in patients with liver fibrosis due to NASH, known as the REGENERATE trial. In the primary efficacy analysis, once-daily OCA 25 mg met the primary endpoint agreed with the U.S. Food and Drug Administration (“FDA”) of fibrosis improvement by at least one | | | ||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | Achieved Significant Worldwide Ocaliva Net Sales. We recognized | | | ||||||||
| | ✓ | | | | Executed $470 million Financing Significantly Strengthening our Financial Position. In May 2019, we issued and sold $230.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2026 and received net | | | ||||||||
| | ✓ | | | | Advanced Leading NASH Development | ||||||||||
| |
| | CEO COMPENSATION HIGHLIGHTS | | | ||||||||||||
| | Our CEO | | | | Break-Down of | | | ||||||||
| | Dr. Mark Pruzanski co-founded our Company and has served as our CEO since our inception in 2002. Dr. Pruzanski has been critical in driving many of our achievements over the course of our history, including those described above. | | | | | | |||||||||
| | ✓ | | | | Market-Based CEO Compensation. For | | | ||||||||
| | ✓ | | | | Significant Performance Elements. We incorporated significant performance elements, including TSR PSUs, into our CEO’s annual and long-term incentive compensation arrangements for | | |
| | ✓ | | | | TSR PSU Grants. | | | ||||||||
| | ✓ | | | | Executive Leadership. Our CEO leads a highly-experienced executive team that spearheaded our business successes described above. | | | ||||||||
| | STOCKHOLDER OUTREACH | | | ||||||||||||
| | Overview. We are committed to establishing and maintaining an open and transparent dialogue with our stockholders with respect to executive compensation and important governance matters. Each year, we engage with our stockholders to request feedback regarding our executive compensation program and other governance matters of importance to our stockholders. Stockholder feedback is then reported to our Compensation Committee, Nominating and Governance Committee and the full Board for consideration. | | | ||||||||||||
| | Stockholder Advisory Vote on Executive Compensation. Each year, our stockholders are provided the opportunity to cast an advisory vote on the compensation of our named executive officers (a “say-on-pay” vote), and our Compensation Committee considers the outcome of the prior year’s say-on-pay vote when making decisions relating to the compensation of our named executive officers and our executive compensation | | | ||||||||||||
| | Stockholder Feedback. We believe that our outreach was well received, and | ||||||||||||||
| |
| | |||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||
| | Commitment to Future Outreach. We believe that stockholder engagement is important and our Compensation Committee will continue to | | | ||||||||||||||||||||||||
| | COMPENSATION AND GOVERNANCE BEST PRACTICES | | | ||||||||||||||||||||||||
| | What We Do | | | ||||||||||||||||||||||||
| | ✓ | | | | Independent Chairman and All Board Members other than our CEO are Independent. Paolo Fundarò serves as our Board’s Chairman, and all of the members of our Board (except Dr. Pruzanski) are independent directors. | | | ||||||||||||||||||||
| | ✓ | | | | Additional Independent Board Leadership and | | | ||||||||||||||||||||
| | ✓ | | | | Independent Compensation Committee. Our Compensation Committee, which is composed entirely of independent directors, provides independent oversight of our compensation programs. | | | ||||||||||||||||||||
| | ✓ | | | | Independent Compensation Consultant. Our Compensation Committee uses an independent executive compensation consulting firm that reports directly to the committee. | | | ||||||||||||||||||||
| | ✓ | | | | Annual Compensation Review and Analysis. Our Compensation Committee conducts an annual assessment of executive compensation to ensure that we provide competitive compensation packages to attract, retain, reward and incentivize our executive management team to achieve success for us and our stockholders. | | |
| | ✓ | | | | Multiple Performance Elements. In accordance with our performance-based compensation philosophy, our executive compensation program incorporates multiple performance elements, including target-based cash incentive bonuses payable upon the achievement of corporate goals and individual performance, and long-term equity incentive compensation, a substantial portion of which consists of stock options and | | | ||||||||
| | ✓ | | | | Market Benchmarking and Use of Reference Peer Group. Our Compensation Committee, with the assistance of its independent compensation consultant, annually analyzes similar life science companies to identify a relevant group of peer companies for purposes of ensuring the reasonableness and competitiveness of our executive compensation program. | | | ||||||||
| | ✓ | | | | Stock Ownership Requirements. We have adopted minimum stock ownership guidelines for our Board, CEO and other executive officers, including our named executive officers, which require, within specified periods of time, our non-employee directors to hold Company equity with a value equal to at least 3x their annual cash retainer and our CEO and other executive officers to hold Company equity with a value equal to at least 3x and 1x, respectively, their annual base salary. | | |
| | ✓ | | | | Clawback Policy. | | | ||||||||
| | ✓ | | | | Corporate Governance Guidelines. In | | | ||||||||
| | What We Don’t Do | | | ||||||||||||
| | ✘ | | | | No excise tax gross-ups. We have not provided or committed to provide excise tax gross-ups to any of our named executive officers. | | | ||||||||
| | ✘ | | | | No change in control “windfalls”. The change in control protections for our named executive officers are limited to “double-trigger” arrangements, which require both a change in control and a qualifying termination of employment, or in the case of TSR PSUs, vesting, if at all, based on our TSR performance relative to that of our TSR Peer Group through the month preceding the month in which the change in control occurs. | | | ||||||||
| | ✘ | | | | Limited perquisites. Our named executive officers generally receive the same benefits as are available to all of our salaried employees, with limited recurring exceptions primarily consisting of fully-paid health insurance premiums. | | | ||||||||
| | ✘ | | | | No automatic or guaranteed annual salary increases. We do not provide for any formulaic or guaranteed base salary increases for our named executive officers. | | | ||||||||
| | ✘ | | | | No guaranteed bonuses or annual equity grants. We do not provide guaranteed bonuses or annual equity grants to our named executive officers. In addition, our Compensation Committee determined to maintain the | | | ||||||||
| | ✘ | | | | No hedging or pledging of Company stock. Our named executive officers and other employees are restricted from engaging in speculative trading activities, including hedging or pledging their company securities as collateral. | | | ||||||||
| ACADIA Pharmaceuticals Inc. | | | Halozyme Therapeutics, Inc. | | | Radius Health, Inc. | |
| Acorda Therapeutics, Inc. | | | Ionis Pharmaceuticals, Inc. | | | Seattle Genetics Inc. | |
| Alkermes plc | | | Lexicon Pharmaceuticals, Inc. | | | Tesaro, Inc. | |
| Alnylam Pharmaceuticals, Inc. | | | Neurocrine Biosciences, Inc. | | | The Medicines Company | |
| bluebird bio, Inc. | | | Omeros Corporation | | | Ultragenyx Pharmaceutical Inc. | |
| Exelixis, Inc. | | | Pacira Pharmaceuticals, Inc. | | | United Therapeutics Corporation | |
| FibroGen, Inc. | | | Puma Biotechnology, Inc. | | |
Named Executive Officer | | | 2019 Salary | | | 2018 Salary | | | Change from 2018 | |
Dr. Mark Pruzanski | | | $734,292 | | | $702,000 | | | 4.6% | |
Sandip Kapadia | | | $464,100 | | | $442,000 | | | 5.0% | |
Jerome Durso | | | $573,250 | | | $540,800 | | | 6.0% | |
Ryan Sullivan | | | $445,520 | | | $424,300 | | | 5.0% | |
Richard Kim | | | $442,900 | | | $430,000 | | | 3.0% | |
2018 Corporate Goal Summary | | | Relative Weighting | | | Assessed Achievement | |
Worldwide Ocaliva Net Sales Target of $203 million | | | 40% | | | 34% | |
NASH Development Program | | | 40% | | | 37% | |
Includes specified activities and milestones related to: | | | | ||||
• the timing of the delivery of topline results from the planned 18-month interim analysis of our pivotal Phase 3 clinical trial of OCA in patients with liver fibrosis due to NASH, known as the REGENERATE trial • conducting our ongoing Phase 3 trial in NASH patients with compensated cirrhosis, known as the REVERSE trial, as well as additional trials and studies in NASH • executing on our regulatory affairs plans for NASH, including preparatory work designed to enable us to file for approval of OCA for NASH in the United States and Europe in the second half of 2019 • developing an integrated strategic plan for NASH | | | | | | | |
Cholestasis Development Program | | | 20% | | | 19% | |
Includes specified activities and milestones related to: | | | | | | | |
• executing on our FDA and EMA post-marketing regulatory commitments and requirements • pursuing certain business and product development initiatives • evaluating our future development strategy and the regulatory pathway for PSC | | | | | | ||
Total | | | 100% | | | 90% | |
|
2019 Corporate Goal Summary | | | Relative Weighting | | | Assessed Achievement | |
NASH Program | | | 60% | | | 59% | |
Includes specified activities and milestones related to: | | | | ||||
• the delivery of topline results from the planned 18-month interim analysis of our pivotal Phase 3 clinical trial of OCA in patients with liver fibrosis due to NASH, known as the REGENERATE trial, and the timing thereof • the acceptance of our NDA in NASH in the United States and the timing thereof • the timely completion of launch preparation and organization ramp-up activities to support a launch of OCA in liver fibrosis due to NASH in the United States, if approved, including the establishment of marketing and medical plans and the creation and appropriate staffing of the launch organization | | | | ||||
PBC Commercial Program | | | 30% | | | 41% | |
Includes specified commercial milestones such as: | | | | ||||
• the achievement of $230 million in worldwide annual net sales of Ocaliva • the achievement of commercial contribution targets in PBC | | | | ||||
Pipeline and New Products | | | 10% | | | 9% | |
Includes specified activities and milestones related to: | | | | | | | |
• the initiation of a Phase 2 study of OCA/bezafibrate combination in PBC • the development and implementation of a pipeline expansion strategy | | | | | | ||
Total | | | 100% | | | 109% | |
| | 2018 Cash Incentive Bonus | | | 2019 Cash Incentive Bonus | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Named Executive Officer | | Target (as % of Base Salary) | | Corporate Goal Achievement Level | | Individual Goal Achievement Level | | Aggregate Achievement (as % of Base Salary) | | Payment | | | Target (as % of Base Salary) | | Corporate Goal Achievement Level | | Individual Goal Achievement Level | | Aggregate Achievement (as % of Base Salary) | | Payment | | ||||||||||||||||||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | 70% | | | | | 90% | | | | | — | | | | | 63% | | | | $ | 442,260 | | | | | | 70% | | | | | 109% | | | | | — | | | | | 76% | | | | $ | 560,265 | | | ||||||||||
Sandip Kapadia | | | | 50% | | | | | 90% | | | | | 115% | | | | | 52% | | | | $ | 228,735 | | | | | | 50% | | | | | 109% | | | | | 100% | | | | | 55% | | | | $ | 252,935 | | | ||||||||||
Jerome Durso | | | | 50% | | | | | 90% | | | | | 120% | | | | | 54% | | | | $ | 292,032 | | | | | | 50% | | | | | 109% | | | | | 115% | | | | | 63% | | | | $ | 359,284 | | | ||||||||||
Ryan Sullivan | | | | 50% | | | | | 90% | | | | | 120% | | | | | 54% | | | | $ | 229,122 | | | | | | 50% | | | | | 109% | | | | | 110% | | | | | 60% | | | | $ | 267,089 | | | ||||||||||
Dr. Gail Cawkwell | | | | 40% | | | | | 90% | | | | | 100% | | | | | 36% | | | | $ | 156,600 | | | ||||||||||||||||||||||||||||||||||||
Richard Kim | | | | 50% | | | | | 109% | | | | | 110% | | | | | 60% | | | | $ | 265,519 | | |
Relative TSR | | | Vesting Percentage | |
Below 25th Percentile | | | 0% | |
25th Percentile | | | 50% | |
50th Percentile | | | 100% | |
75th Percentile and Above | | | 150% | |
Named Executive Officer | | | TSR PSUs | | | Stock Options | | | Restricted Stock Units | | |||||||||
Dr. Mark Pruzanski | | | | | 23,400 | | | | | | 45,500 | | | | | | — | | |
Sandip Kapadia | | | | | 5,400 | | | | | | 10,500 | | | | | | 6,900 | | |
Jerome Durso | | | | | 10,600 | | | | | | 20,700 | | | | | | 13,600 | | |
Named Executive Officer | | Stock Options | | Restricted Stock/Units | | | TSR PSUs | | Stock Options | | Restricted Stock Units | | ||||||||||||||||||||
Dr. Mark Pruzanski | | | | 23,300 | | | | | 13,700 | | | | | 8,500 | | | ||||||||||||||||
Sandip Kapadia | | | | 3,600 | | | | | 7,200 | | | | | 4,500 | | | ||||||||||||||||
Jerome Durso | | | | 7,500 | | | | | 15,200 | | | | | 9,400 | | | ||||||||||||||||
Ryan Sullivan | | | | 35,300 | | | | | 23,200 | | | | | | 5,300 | | | | | 10,700 | | | | | 6,600 | | | |||||
Dr. Gail Cawkwell | | | | 22,925 | | | | | 15,025 | | | |||||||||||||||||||||
Richard Kim | | | | 3,200 | | | | | 6,400 | | | | | 4,000 | | |
Named Executive Officer | | | 2020 Salary | | | 2019 Salary | | | Change from 2020 | |
Dr. Mark Pruzanski | | | $759,992 | | | $734,292 | | | 3.50% | |
Sandip Kapadia | | | $478,023 | | | $464,100 | | | 3.00% | |
Jerome Durso | | | $601,913 | | | $573,250 | | | 5.00% | |
Ryan Sullivan | | | $461,113 | | | $445,520 | | | 3.50% | |
Richard Kim | | | $457,294 | | | $442,900 | | | 3.25% | |
Named Executive Officer | | | Target Cash Incentive Bonus (as % of Base Salary) | | |||
Dr. Mark Pruzanski | | | | | 70% | | |
Sandip Kapadia | | | | | 50% | | |
Jerome Durso | | | | | 50% | | |
Ryan Sullivan | | | | | 50% | | |
| | | | | |
Named Executive Officer | | TSR PSUs | | Stock Options | | Restricted Stock Units | | | TSR PSUs | | Stock Options | | Restricted Stock Units | | ||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | 23,300 | | | | | 13,700 | | | | | 8,500 | | | | | | 25,800 | | | | | 17,700 | | | | | 10,800 | | | ||||||
Sandip Kapadia | | | | 3,600 | | | | | 7,200 | | | | | 4,500 | | | | | | 4,500 | | | | | 9,200 | | | | | 5,600 | | | ||||||
Jerome Durso | | | | 7,500 | | | | | 15,200 | | | | | 9,400 | | | | | | 8,500 | | | | | 17,400 | | | | | 10,600 | | | ||||||
Ryan Sullivan | | | | 5,300 | | | | | 10,700 | | | | | 6,600 | | | | | | 4,500 | | | | | 9,200 | | | | | 5,600 | | | ||||||
Dr. Gail Cawkwell | | | | 3,300 | | | | | 6,700 | | | | | 4,100 | | | ||||||||||||||||||||||
Richard Kim | | | | 4,300 | | | | | 8,800 | | | | | 5,400 | | |
Relative TSR | | | Vesting Percentage | |
Below 25th Percentile | | | 0% | |
25th Percentile | | | 50% | |
50th Percentile | | | 100% | |
75th Percentile and Above | | | 150% | |
Name and Principal Position | | Year(1) | | Salary ($)(2) | | Bonus ($)(3) | | Stock Awards ($)(4) | | Option Awards ($)(4) | | Non-Equity Incentive Plan Compensation ($)(5) | | All Other Compensation ($)(6) | | Total ($) | | | Year(1) | | Salary ($)(2) | | Bonus ($)(3) | | Stock Awards ($)(4) | | Option Awards ($)(4) | | Non-Equity Incentive Plan Compensation ($)(5) | | All Other Compensation ($)(6) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Mark Pruzanski President and Chief Executive Officer | | | | | 2018 | | | | | 702,000 | | | | | — | | | | | 1,667,718 | | | | | 1,705,358 | | | | | 442,260 | | | | | 8,623 | | | | | 4,525,960 | | | | | | | 2019 | | | | | 734,292 | | | | | — | | | | | 4,197,742 | | | | | 1,116,118 | | | | | 560,265 | | | | | 7,368 | | | | | 6,615,785 | | | ||||||||||||||
| | | 2017 | | | | | 675,000 | | | | | — | | | | | 2,486,576 | | | | | 2,583,556 | | | | | 401,625 | | | | | 7,930 | | | | | 6,154,687 | | | | | | 2018 | | | | | 702,000 | | | | | — | | | | | 1,667,718 | | | | | 1,705,358 | | | | | 442,260 | | | | | 8,623 | | | | | 4,525,960 | | | |||||||||||||||||
| | | 2016 | | | | | 620,000 | | | | | — | | | | | 2,196,957 | | | | | 1,608,449 | | | | | 347,000 | | | | | 4,627 | | | | | 4,777,033 | | | | | | 2017 | | | | | 675,000 | | | | | — | | | | | 2,486,576 | | | | | 2,583,556 | | | | | 401,625 | | | | | 7,930 | | | | | 6,154,687 | | | |||||||||||||||||
Sandip Kapadia Chief Financial Officer and Treasurer | | | | | 2018 | | | | | 442,000 | | | | | — | | | | | 790,164 | | | | | 393,544 | | | | | 228,735 | | | | | 22,403 | | | | | 1,876,847 | | | | | | | 2019 | | | | | 464,100 | | | | | — | | | | | 1,001,664 | | | | | 586,573 | | | | | 252,935 | | | | | 21,368 | | | | | 2,326,640 | | | ||||||||||||||
| | | 2017 | | | | | 425,000 | | | | | — | | | | | 750,260 | | | | | 749,231 | | | | | 188,594 | | | | | 23,930 | | | | | 2,137,016 | | | | | | 2018 | | | | | 442,000 | | | | | — | | | | | 790,164 | | | | | 393,544 | | | | | 228,735 | | | | | 22,403 | | | | | 1,876,846 | | | |||||||||||||||||
| | | 2016 | | | | | 200,000 | | | | | 75,000 | | | | | 2,195,400 | | | | | 1,559,019 | | | | | 183,000 | | | | | 7,057 | | | | | 4,219,476 | | | | | | 2017 | | | | | 425,000 | | | | | — | | | | | 750,260 | | | | | 749,231 | | | | | 188,594 | | | | | 23,930 | | | | | 2,137,016 | | | |||||||||||||||||
Jerome Durso Chief Operating Officer | | | | | 2018 | | | | | 540,800 | | | | ��� | — | | | | | 1,554,326 | | | | | 775,844 | | | | | 292,032 | | | | | 22,403 | | | | | 3,185,406 | | | | | | | 2019 | | | | | 573,250 | | | | | — | | | | | 2,089,570 | | | | | 1,238,321 | | | | | 359,284 | | | | | 21,368 | | | | | 4,281,793 | | | ||||||||||||||
| | | 2017 | | | | | 441,333 | | | | | — | | | | | 1,738,950 | | | | | 1,395,217 | | | | | 260,000 | | | | | 26,765 | | | | | 3,862,266 | | | | | | 2018 | | | | | 540,800 | | | | | — | | | | | 1,554,326 | | | | | 775,844 | | | | | 292,032 | | | | | 22,403 | | | | | 3,185,406 | | | |||||||||||||||||
| | | | 2017 | | | | | 441,333 | | | | | — | | | | | 1,738,950 | | | | | 1,395,217 | | | | | 260,000 | | | | | 26,765 | | | | | 3,862,266 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan General Counsel and Secretary | | | | 2018 | | | | | 376,158 | | | | | — | | | | | 1,239,112 | | | | | 1,190,351 | | | | | 229,122 | | | | | 173,437 | | | | | 3,208,180 | | | | | | | 2019 | | | | | 445,520 | | | | | — | | | | | 1,471,902 | | | | | 871,713 | | | | | 267,089 | | | | | 21,368 | | | | | 3,077,592 | | | |||||||||||||||
Dr. Gail Cawkwell SVP, Medical Affairs, Safety & Pharmacovigilance | | | | 2018 | | | | | 387,317 | | | | | — | | | | | 820,816 | | | | | 788,283 | | | | | 156,600 | | | | | 21,682 | | | | | 2,174,698 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan General Counsel and Secretary | | | | | 2018 | | | | | 376,158 | | | | | — | | | | | 1,239,112 | | | | | 1,190,351 | | | | | 229,122 | | | | | 173,437 | | | | | 3,208,180 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 442,900 | | | | | 202,800 | | | | | 890,368 | | | | | 521,398 | | | | | 265,519 | | | | | 76,343 | | | | | 2,399,328 | | |
Name | | Contributions Under 401(k) Plan ($)(i) | | Health Insurance ($)(ii) | | Relocation Expenses ($)(iii) | | | Contributions Under 401(k) Plan ($)(i) | | Health Insurance ($)(ii) | | Miscellaneous ($)(iii) | | ||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | — | | | | | 8,623 | | | | | — | | | | | | — | | | | | 7,368 | | | | | — | | | ||||||
Sandip Kapadia | | | | 13,750 | | | | | 8,653 | | | | | — | | | | | | 14,000 | | | | | 7,368 | | | | | — | | | ||||||
Jerome Durso | | | | 13,750 | | | | | 8,653 | | | | | — | | | | | | 14,000 | | | | | 7,368 | | | | | — | | | ||||||
Ryan Sullivan | | | | 13,750 | | | | | 7,932 | | | | | 151,755 | | | | | | 14,000 | | | | | 7,368 | | | | | — | | | ||||||
Dr. Gail Cawkwell | | | | 13,750 | | | | | 7,932 | | | | | — | | | ||||||||||||||||||||||
Richard Kim | | | | 14,000 | | | | | 7,368 | | | | | 54,975 | | |
Name | | Grant Date | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(4) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(5) | | | All Other Stock Awards: Number of Shares of Stock (#)(7) | | All Other Option Awards: Number of Securities Underlying Options (#)(8) | | Exercise or Base Price of Option Awards ($/Sh)(9) | | Grant Date Fair Value of Stock and Option Awards ($)(10) | | | Grant Date | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(2) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(3) | | | All Other Stock Awards: Number of Shares of Stock (#)(5) | | All Other Option Awards: Number of Securities Underlying Options (#)(6) | | Exercise or Base Price of Option Awards ($/Sh)(7) | | Grant Date Fair Value of Stock and Option Awards ($)(8) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Threshold (#)(6) | | Target (#) | | Maximum (#) | | | Threshold (#)(4) | | Target (#) | | Maximum (#) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | | — | | | | | 514,004 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 491,400 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 01/16/19(1) | | | | | — | | | | | 11,650 | | | | | 23,300 | | | | | 34,950 | | | | | — | | | | | — | | | | | — | | | | | 3,255,942 | | | ||||||||||||||||||
| | | 02/05/18(1) | | | | | — | | | | | 11,700 | | | | | 23,400 | | | | | 35,100 | | | | | — | | | | | — | | | | | — | | | | | 1,667,718 | | | | | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,500 | | | | | 13,700 | | | | | 110.80 | | | | | 941,800 | | | |||||||||||||||||||
| | | 02/05/18(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 45,500 | | | | | 58.74 | | | | | 1,705,358 | | | | | | 01/16/19(1) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,116,118 | | | |||||||||||||||||||
Sandip Kapadia | | | | | — | | | | | 221,000 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | 232,050 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||
| | | 02/05/18(1) | | | | | — | | | | | 2,700 | | | | | 5,400 | | | | | 8,100 | | | | | — | | | | | — | | | | | — | | | | | 384,858 | | | | | | 01/16/19(1) | | | | | — | | | | | 1,800 | | | | | 3,600 | | | | | 5,400 | | | | | — | | | | | — | | | | | — | | | | | 503,064 | | | |||||||||||||||||||
| | | 02/05/18(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 6,900 | | | | | — | | | | | — | | | | | 405,306 | | | | | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 4,500 | | | | | — | | | | | — | | | | | 498,600 | | | |||||||||||||||||||
| | | 02/05/18(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,500 | | | | | 58.74 | | | | | 393,544 | | | | | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 7,200 | | | | | 110.80 | | | | | 586,573 | | | |||||||||||||||||||
Jerome Durso | | | | | — | | | | | 270,400 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | 286,625 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||
| | | 02/05/18(1) | | | | | — | | | | | 5,300 | | | | | 10,600 | | | | | 15,900 | | | | | — | | | | | — | | | | | — | | | | | 755,462 | | | | | | 01/16/19(1) | | | | | — | | | | | 3,750 | | | | | 7,500 | | | | | 11,250 | | | | | — | | | | | — | | | | | — | | | | | 1,048,050 | | | |||||||||||||||||||
| | | 02/05/18(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 13,600 | | | | | — | | | | | — | | | | | 798,864 | | | | | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 9,400 | | | | | — | | | | | — | | | | | 1,041,520 | | | |||||||||||||||||||
| | | 02/05/18(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 20,700 | | | | | 58.74 | | | | | 775,844 | | | | | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 15,200 | | | | | 110.80 | | | | | 1,238,321 | | | |||||||||||||||||||
Ryan Sullivan | | | | | — | | | | | 212,150 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | 222,760 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||
| | | 02/13/18(2) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 23,200 | | | | | — | | | | | — | | | | | 1,239,112 | | | | | | 01/16/19(1) | | | | | — | | | | | 2,650 | | | | | 5,300 | | | | | 7,950 | | | | | | | | | | — | | | | | — | | | | | 740,622 | | | |||||||||||||||||||
| | | 02/13/18(2) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 35,300 | | | | | 53.41 | | | | | 1,190,351 | | | | | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 6,600 | | | | | 10,700 | | | | | 110.80 | | | | | 731,280 | | | |||||||||||||||||||
Dr. Gail Cawkwell | | | | | — | | | | | 174,000 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/12/18(3) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 15,025 | | | | | — | | | | | — | | | | | 820,816 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/12/18(3) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 22,925 | | | | | 54.63 | | | | | 788,283 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan | | | | | 01/16/19(1) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 871,713 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | — | | | | | 221,450 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | 1,600 | | | | | 3,200 | | | | | 4,800 | | | | | | | | | | — | | | | | — | | | | | 447,168 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 4,000 | | | | | | | | | | | | | | | 443,200 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Richard Kim | | | | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 6,400 | | | | | 110.80 | | | | | 521,398 | | |
| | Option Awards | | | | Stock Awards | | | Option Awards | | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable(12) | | Option Exercise Price ($) | | Option Expiration Date | | | | Number of Shares or Units of Stock That Have Not Vested (#)(16) | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)(25) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable(13) | | Option Exercise Price ($) | | Option Expiration Date | | | | Number of Shares or Units of Stock That Have Not Vested (#)(14) | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)(22) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | | 39(1) | | | | | — | | | | | 8.6667 | | | | | 08/16/20 | | | | | | | 944(17) | | | | | 95,146 | | | | | 35,100(26) | | | | | 3,537,729 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 34,404(2) | | | | | — | | | | | 8.6667 | | | | | 10/13/21 | | | | | | | 7,281(18) | | | | | 733,852 | | | | | — | | | | | — | | | | | | | 30,084(1) | | | | | — | | | | | 21.50 | | | | | 11/16/22 | | | | | | | 1,456(15) | | | | | 180,428 | | | | | 35,100(23) | | | | | 4,349,592 | | | ||||||||||||||
| | | 46,158(3) | | | | | — | | | | | 21.50 | | | | | 11/16/22 | | | | | | | 13,050(19) | | | | | 1,315,310 | | | | | — | | | | | — | | | | | | 62,595(2) | | | | | — | | | | | 31.90 | | | | | 05/07/23 | | | | | | | 7,250(16) | | | | | 898,420 | | | | | 34,950(24) | | | | | 4,331,004 | | | |||||||||||||||
| | | 62,595(4) | | | | | — | | | | | 31.90 | | | | | 05/07/23 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 5,733(3) | | | | | — | | | | | 266.01 | | | | | 04/11/24 | | | | | | | 6,375(17) | | | | | 789,990 | | | | | — | | | | | — | | | |||||||||||||||
| | | 5,733(5) | | | | | — | | | | | 266.01 | | | | | 04/11/24 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | 5,733(3) | | | | | 266.01 | | | | | 04/11/24 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||
| | | 11,465(6) | | | | | 11,466(6) | | | | | 266.01 | | | | | 04/11/24 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 32,550(4) | | | | | — | | | | | 161.16 | | | | | 10/01/25 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||
| | | 31,872(7) | | | | | 678(7) | | | | | 161.16 | | | | | 10/01/25 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 29,865(5) | | | | | 635(5) | | | | | 94.29 | | | | | 02/11/26 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||
| | | 22,240(8) | | | | | 8,260(8) | | | | | 94.29 | | | | | 02/11/26 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 29,167(6) | | | | | 10,833(6) | | | | | 107.18 | | | | | 02/01/27 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||
| | | 19,167(9) | | | | | 20,833(9) | | | | | 107.18 | | | | | 02/01/27 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 21,801(7) | | | | | 23,699(7) | | | | | 58.74 | | | | | 02/05/28 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||
| | | — | | | | | 45,500(13) | | | | | 58.74 | | | | | 02/05/28 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 3,425(8) | | | | | 10,275(8) | | | | | 110.80 | | | | | 01/16/29 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||
Sandip Kapadia | | | | | 10,875(10) | | | | | 7,125(10) | | | | | 146.36 | | | | | 07/01/26 | | | | | | | 6,562(20) | | | | | 661,384 | | | | | 8,100(26) | | | | | 816,399 | | | | | | | 15,375(9) | | | | | 2,625(9) | | | | | 146.36 | | | | | 07/01/26 | | | | | | | 2,812(18) | | | | | 348,463 | | | | | 8,100(23) | | | | | 1,003,752 | | | ||||||||||||
| | | 5,558(9) | | | | | 6,042(9) | | | | | 107.18 | | | | | 02/01/27 | | | | | | | 3,937(19) | | | | | 396,810 | | | | | — | | | | | — | | | | | | 8,458(6) | | | | | 3,142(6) | | | | | 107.18 | | | | | 02/01/27 | | | | | | | 2,187(16) | | | | | 271,013 | | | | | 5,400(24) | | | | | 669,168 | | | |||||||||||||||
| | | — | | | | | 10,500(13) | | | | | 58.74 | | | | | 02/05/28 | | | | | | | 6,900(21) | | | | | 695,451 | | | | | — | | | | | — | | | | | | 5,030(7) | | | | | 5,470(7) | | | | | 58.74 | | | | | 02/05/28 | | | | | | | 3,882(19) | | | | | 481,057 | | | | | — | | | | | — | | | |||||||||||||||
Sandip Kapadia | | | | 1,800(8) | | | | | 5,400(8) | | | | | 10.80 | | | | | 01/16/29 | | | | | | | 3,375(17) | | | | | 418,230 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 14,167(10) | | | | | 5,833(10) | | | | | 115.93 | | | | | 02/23/27 | | | | | | | 4,687(20) | | | | | 580,813 | | | | | 15,900(23) | | | | | 1,970,328 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 9,167(11) | | | | | 10,833(11) | | | | | 115.93 | | | | | 02/23/27 | | | | | | | 8,437(22) | | | | | 850,365 | | | | | 15,900(26) | | | | | 1,602,561 | | | | | | 9,918(7) | | | | | 10,782(7) | | | | | 58.74 | | | | | 02/05/28 | | | | | | | 7,650(19) | | | | | 947,988 | | | | | 11,250(24) | | | | | 1,394,100 | | | ||||||||||||||
| | | — | | | | | 20,700(13) | | | | | 58.74 | | | | | 02/05/28 | | | | | | | 13,600(21) | | | | | 1,370,744 | | | | | — | | | | | — | | | | | | 3,800(8) | | | | | 11,400(8) | | | | | 110.80 | | | | | 01/16/29 | | | | | | | 7,050(17) | | | | | 873,636 | | | | | — | | | | | — | | | |||||||||||||||
Ryan Sullivan | | | | — | | | | | 35,300(14) | | | | | 53.41 | | | | | 02/13/28 | | | | | | | 23,200(23) | | | | | 2,338,328 | | | | | — | | | | | — | | | | | | | 7,353(11) | | | | | 19,122(11) | | | | | 53.41 | | | | | 02/13/28 | | | | | | | 13,050(21) | | | | | 1,617,156 | | | | | 7,950(24) | | | | | 985,164 | | | |||||||||||||
Dr. Gail Cawkwell | | | | — | | | | | 22,925(15) | | | | | 54.63 | | | | | 02/12/28 | | | | | | | 15,025(24) | | | | | 1,514,370 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan | | | | | 2,675(8) | | | | | 8,025(8) | | | | | 110.80 | | | | | 01/16/29 | | | | | | | 4,950(17) | | | | | 613,404 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4,395(12) | | | | | — | | | | | 277.61 | | | | | 07/18/25 | | | | | | | 127(15) | | | | | 15,738 | | | | | 6,750(23) | | | | | 836,460 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Richard Kim | | | | | 4,015(5) | | | | | 85(5) | | | | | 94.29 | | | | | 02/11/26 | | | | | | | 1,469(16) | | | | | 182,038 | | | | | 4,800(24) | | | | | 594,816 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 5,363(6) | | | | | 2,437(6) | | | | | 107.18 | | | | | 02/01/27 | | | | | | | 3,263(19) | | | | | 404,350 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4,216(7) | | | | | 4,584(7) | | | | | 58.74 | | | | | 02/05/28 | | | | | | | 3,000(17) | | | | | 371,760 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1,600(8) | | | | | 4,800(8) | | | | | 110.80 | | | | | 01/16/29 | | | | | | | | | | | | | | | | | | | | | | | | |
| | Option Awards | | Stock Awards | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||
Name | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise ($)(1) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($)(2) | | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise ($)(1) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($)(2) | | ||||||||||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | 50,000 | | | | | 4,620,378 | | | | | 20,044 | | | | | 1,542,953 | | | | | | 50,517 | | | | | 4,420,527 | | | | | 14,694 | | | | | 1,396,956 | | | ||||||||
Sandip Kapadia | | | | — | | | | | — | | | | | 6,813 | | | | | 530,927 | | | | | | — | | | | | — | | | | | 9,643 | | | | | 915,168 | | | ||||||||
Jerome Durso | | | | — | | | | | — | | | | | 6,563 | | | | | 503,305 | | | | | | — | | | | | — | | | | | 12,050 | | | | | 1,160,076 | | | ||||||||
Ryan Sullivan | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 8,825 | | | | | 278,782 | | | | | 11,800 | | | | | 1,183,334 | | | ||||||||
Dr. Gail Cawkwell | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Richard Kim | | | | — | | | | | — | | | | | 5,896 | | | | | 575,258 | | |
Plan Category | | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | | | Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights | | | Number of Securities Remaining Available for Future Issuance | | |||||||||
Equity Compensation Plans Approved by Security Holders(1) | | | | | | | | | $ | | | | | | | | |||
Equity Compensation Plans Not Approved by Security Holders | | | | | — | | | | | | — | | | | | | — | | |
Name | | | | | | Termination Due to Death ($)(4) | | | Termination Due to Disability ($)(5) | | | Termination Without Cause or Resignation for Good Reason ($)(6) | | | Termination Without Cause or Resignation for Good Reason In Connection with a Change of Control ($)(7) | |
Dr. Mark Pruzanski | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | 514,004 | | | 1,248,296 | | | 1,131,254 | | | 2,262,507 | |
| | | Value of Accelerated Vesting(2) | | | 12.429,102 | | | 12,429,102 | | | 12,429,102 | | | 12,429,102 | |
| | | Health Insurance Benefits(3) | | | — | | | 34,283 | | | 34,283 | | | 34,283 | |
| | | Total | | | 12,943,106 | | | 13,711,681 | | | 13,594,639 | | | 14,725,892 | |
Sandip Kapadia | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 464,100 | | | 464,100 | |
| | | Value of Accelerated Vesting(2) | | | 594,816 | | | 594,816 | | | 1,161,755 | | | 3,671,663 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 34,283 | | | 34,283 | |
| | | Total | | | 594,816 | | | 594,816 | | | 1,660,138 | | | 4,170,046 | |
Jerome Durso | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 573,250 | | | 573,250 | |
| | | Value of Accelerated Vesting(2) | | | 1,185,501 | | | 1,185,501 | | | 1,604,353 | | | 6,665,809 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 34,283 | | | 34,283 | |
| | | Total | | | 1,185,501 | | | 1,185,501 | | | 2,211,886 | | | 7,273,342 | |
Ryan Sullivan | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 445,520 | | | 445,520 | |
| | | Value of Accelerated Vesting(2) | | | 218,925 | | | 218,925 | | | 1,580,551 | | | 4,669,304 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 34,283 | | | 34,283 | |
| | | Total | | | 218,925 | | | 218,925 | | | 2,060,354 | | | 5,149,107 | |
Richard Kim | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 442,900 | | | 442,900 | |
| | | Value of Accelerated Vesting(2) | | | 503,941 | | | 503,941 | | | — | | | 2,810,238 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 34,283 | | | 34,283 | |
| | | Total | | | 503,941 | | | 503,941 | | | 477,183 | | | 3,287,421 | |
| | Year Ended December 31, | | | Year Ended December 31, | | ||||||||||||||||||||
| | 2018 | | 2017 | | | 2019 | | 2018 | | ||||||||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||||||||
Audit Fees | | | $ | 1,474 | | | | $ | 1,415 | | | | | $ | 1,777 | | | | $ | 1,491 | | | ||||
Audit-Related Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Tax Fees | | | | 94 | | | | | 127 | | | | | | 146 | | | | | 94 | | | ||||
All Other Fees | | | | 2 | | | | | — | | | | | | 2 | | | | | 2 | | | ||||
Total Fees | | | $ | 1,570 | | | | $ | 1,542 | | | | | $ | 1,925 | | | | $ | 1,587 | | | ||||
|